School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Legend Biotech Corporation LEGN

Healthcare · Biotechnology

18.62 (local currency)last close 2026-10-09 · delayed data

Trailing returns

1M-6.48%
3M-31.99%
6M+2.31%
1Y-42.21%
5Y-65.22%

Basis: Adjusted daily closes.

What it does

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).

Open LEGN in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies